Orca Bio operates in the biotechnology field, specifically focusing on cell therapies that utilize the body's own cells to treat diseases. The company aims to enhance these therapies to make them safer and more effective, ultimately improving patient outcomes. Orca Bio's products are designed for healthcare providers who administer these therapies to patients as part of their treatment plans. Unlike many competitors, Orca Bio emphasizes a strong team culture and values communication with stakeholders, keeping them informed about the company's progress and developments. The goal of Orca Bio is to significantly impact healthcare by advancing cell therapy treatments for conditions that currently have limited options.

DCVC

+ND Capital

Lightspeed Venture Partners

IMRF

Kaiser Permanente

Mubadala Capital

Biotechnology

Healthcare

Orca Bio

The field of stem cell therapy has gained traction over recent years, with companies transitioning from experimental stages to delivering practical treatments. Stem cells, with their unique ability to differentiate into various cell types, hold great potential in regenerative medicine.One of the most notable advancements in stem cell therapy is its application in treating neurodegenerative diseases such as Parkinson’s disease. Companies like BlueRock Therapeutics have pioneered the development of dopamine-producing neural cells derived from stem cells potentially altering the disease course​. Stem cell therapy has also shown potential in repairing damaged heart tissue or in cancer treatment research.In this article, we delve into stem-cell-oriented biotech companies to know about.Table of contentsAspen NeuroscienceAspen Neuroscience was founded in 2018, and is headquartered in San Diego. It is a clinical-stage company focused on developing personalized stem cell therapies to treat neurodegenerative diseases, with an initial emphasis on Parkinson’s disease.Aspen Neuroscience’s lead candidate, ANPD001, is an autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy aimed at treating Parkinson’s disease. This therapy is designed to replace the lost dopamine neurons that are characteristic of the disease, potentially reversing its effects.Aspen’s technology lies in the use of autologous iPSCs

Stem Cell Therapy’S Avant-Garde: Eight Companies Leading The Way

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced new data will be presented during the 50th Annual Meeting of the EBMT in Glasgow, United Kingdom. Specifically, results from a single-center open-label Phase 1 clinical trial of an expanded group of older patients (n=20) treated with Orca Bio’s lead investigational high-precision cell therapy, Orca-T, and a reduced intensity conditioning (RIC) regimen will be presented. Preliminary data with Orca-T and RIC in patients with hematologic malignancies showed encouraging rates of relapse-free survival (77%). With a median follow-up of 9.65 months, no patients have experienced relapse to date (0%), demonstrating the curative potential for Orca-T in this historically challenging to treat patient group. An earlier dataset evaluating Orca-T and RIC in this population was presented at the 2023 American Society of Hematology (ASH) Annual Meeting. A second presentation will highlight findings from a non-randomized retrospective analysis comparing Orca-T plus single-agent tacrolimus with a standard of care allogeneic stem cell transplant (alloHSCT) plus post-transplant cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis in patients with hematologic malignancies receiving myeloablative conditioning (MAC)

Orca Bio To Present Positive Clinical Data On Orca-T At The 50Th Annual Meeting Of The Ebmt

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced positive data on its lead investigational high-precision cell therapy, Orca-T, presented at the 2024 Tandem Meetings, Transplantation  Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). In the first of two oral presentations, findings from a retrospective analysis compared historical outcomes between Orca-T and a standard of care allogeneic stem cell transplant (alloHSCT) plus post-transplant cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis in patients with hematologic malignancies receiving myeloablative conditioning (MAC). Within the non-randomized cohorts of varying conditioning regimens and disease types, Orca-T demonstrated favorable results across clinical outcomes including relapse-free survival (RFS), non-relapse mortality (NRM) and overall survival (OS). “When treating hematological malignancies, physicians are often faced with compromising between the risk of relapse and the risk of serious toxicities, all of which can impact overall patient survival,” said Alexandra Gomez-Arteaga, MD, Assistant Professor of Medicine at Weill Cornell Medicine, hematologist oncologist in the Bone Marrow Transplant and Cellular Therapy Program at NewYork-Presbyterian/Weill Cornell Medical Center, and presenting author. “While advances in prophylaxis agents have demonstrated improvements in reducing the rate of graft versus host disease, the findings of this retrospective analysis suggest Orca-T may also provide benefits across key survival metrics, further highlighting the importance of identifying novel approaches that may offer enhancements across all patient outcomes.”

Orca Bio Presents Promising Data On Orca-T In Two Oral Presentations At The 2024 Tandem Meetings Of Astct® And Cibmtr®

– The first oral presentation will demonstrate the performance of Orca-T in patients over 55 years of age compared with younger patients –– A second oral presentation will highlight Orca-Q, Orca Bio’s high-precision cell therapy for patients with haploidentical donors –– Additional poster presentations include outcomes in patients with high-risk myelodysplastic syndrome treated with Orca-T and results of Orca-T in patients undergoing reduced intensity conditioning –MENLO PARK, Calif.--(BUSINESS WIRE)-- Orca Biosystems, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced that new data will be presented at the American Society of Hematology (ASH) Annual Meeting from December 9-12 in San Diego, CA. Specifically, an oral presentation will highlight the outcomes of myeloablative Orca-T, Orca Bio’s lead investigational high-precision cell therapy, in patients over the age of 55. A second oral presentation will share updated results in an expanded group of patients with haploidentical donors treated with Orca Bio’s second investigational high-precision cell therapy, Orca-Q.Orca Bio will also present two posters highlighting the results of patients with high-risk myelodysplastic syndrome who were treated with Orca-T, and the outcomes of patients treated with Orca-T who received reduced intensity conditioning.The ASH abstracts are now available at www.hematology.org. Details of the Orca Bio presentations follow:Oral Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia. Title: Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients  55 Years Old with Hematologic Malignancies

Orca Bio To Present Positive Clinical Data On Its Novel High-Precision Cell Therapies At The 65Th American Society Of Hematology Annual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)-- Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced that Ivan Dimov, Ph.D., Orca Bio’s co-founder and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference.The company presentation will take place on Monday, January 8, 2024, at 2:00PM PST at the Westin St. Francis in the Golden Gate Room on the 32nd floor.About Orca BioOrca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. Our investigational products are designed to safely replace a patient’s diseased blood and immune system with a healthy one, delivering significantly better outcomes with dramatically fewer risks than the standard of care. Our manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products that have the potential to transform allogeneic cell therapy. At Orca Bio, our mission is to make curative cell therapies both more effective and safer, and in doing so, push past the field’s current boundaries and redefine its future

Orca Bio To Present At The 42Nd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)-- Orca Biosystems, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, today announced that Ivan Dimov, Ph.D., Orca Bio’s co-founder and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference.The company presentation will take place on Monday, January 9, 2023, at 7:30 a.m. PST at the Westin St. Francis in the Mission Bay Room on the 32nd Floor.About Orca BioOrca Bio is a late-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. Our investigational therapies are designed to deliver better survival rates with dramatically fewer risks than standard allogeneic stem cell transplants, like graft versus host disease and other debilitating transplant-related toxicities. At Orca Bio, we hope to not only replace patients' blood and immune systems with healthy ones, but restore their quality of life

Orca Bio To Present At The 41St Annual J.P. Morgan Healthcare Conference

– Three oral presentations showcase clinical evidence for Orca Bio’s promising pipeline of early- and late-stage high-precision cell therapies –– Orca-T demonstrated high relapse-free survival in recipients with fully matched donors and early potential in patients with mismatched donors –– Orca-Q showed improved graft-versus-host disease-free, relapse-free survival in patients with haploidentical donors –. MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, today announced data from the company’s investigational high-precision cell therapy programs, Orca-T and Orca-Q, were presented in three oral presentations at the 2023 Transplantation  Cellular Therapy Meetings of ASTCT and CIBMTR.Positive data on Orca-T was presented from the single-center Phase 2 and multi-center Phase 1b trials of patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndromes (MDS) and other hematological malignancies. Outcomes with Orca-T appeared to be further enhanced in patients who received a conditioning regimen of busulfan, fludarabine and thiotepa (BFT). At 12 months, the 71 patients in the Orca-T BFT subgroup reported no non-relapse mortality (0%), and high rates of relapse-free survival (87%), graft-versus-host disease-free, relapse-free survival (GRFS) (81%) and overall survival (94%). These data were previously presented at the 64th American Society of Hematology (ASH) Annual Meeting in December 2022.In a second oral presentation, new data highlighted how expanding the donor pool may help address disparities in access to transplant. Today, approximately 70% of blood cancer patients do not have access to a fully matched related donor, and the likelihood of a patient finding a matched unrelated donor in the U.S

Orca Bio Presents Positive Data Reinforcing Clinical Profile Of Orca-T And Orca-Q At 2023 Transplantation & Cellular Therapy Meetings Of Astct And Cibmtr

– Orca-Q is Orca Bio’s investigational high-precision cell therapy designed to overcome the challenges of haploidentical allogeneic hematopoietic stem cell transplant (alloHSCT) –– Interim multi-center Phase 1 clinical trial results show that Orca-Q improved graft-versus-host disease-free, relapse-free survival in haploidentical alloHSCT compared to standard of care, without use of post-transplant cyclophosphamide –. MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, today announced that interim clinical data from its Phase 1 multi-center trial of its second investigational cell therapy, Orca-Q, were unveiled in an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting.The data from the ongoing clinical trial show that Orca-Q reduced the incidence and severity of graft versus host disease (GvHD) and improved graft-versus-host disease-free, relapse-free survival (GRFS) rates in 26 patients matched to haploidentical allogeneic hematopoietic stem cell donors. Unlike standard of care haploidentical allogeneic hematopoietic stem transplant (alloHSCT), Orca-Q does not require post-transplant cyclophosphamide (PTCy).“Patients and transplant physicians are in urgent need of a novel treatment option that improves the chances of survival and the quality of that survival. This is the key limitation of haploidentical transplant, which is currently the only treatment option for the vast majority of blood cancer patients in need of a transplant,” said Amandeep Salhotra, M.D., associate professor, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope. “These results suggest Orca-Q’s promise to overcome this serious challenge by offering a novel investigational high-precision cell therapy with the potential to significantly improve patient outcomes and reduce serious transplant-related risks.”Orca-Q is an investigational high-precision cell therapy that is a proprietary composition of enriched CD34+ stem cells combined with specific T cell subsets. The findings presented at ASH are from patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and chronic myeloid leukemia (CML) who were matched to haploidentical allogeneic donors, defined as matched across at least 4/8 but fewer than 7/8 human leukocyte antigen (HLA) loci

Orca Bio Presents Encouraging Interim Clinical Data On Orca-Q In Haploidentical Allogeneic Hematopoietic Stem Cell Transplants At 64Th Ash Annual Meeting

– Updated data from Phase 1b/2 trials include 151 patients with acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes and other hematological malignancies –– Relapse-free survival was 87% at one year in a group of 71 patients who received the preferred conditioning regimen being used in the Precision-T Phase 3 Study of Orca-T –– Data also showed improved graft-versus-host disease-free, relapse-free survival rates and overall survival rates at one year with Orca-T compared to standard of care –– Precision-T pivotal Phase 3 study is ongoing and enrolling patients at transplant centers across U.S. –. MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, today presented updated positive clinical data on its lead investigational cell therapy, Orca-T, during an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting.The data demonstrated a significant improvement in relapse-free survival (RFS) at one year with 87% in 71 patients who received Orca-T and busulfan, fludarabine and thiotepa (BFT) conditioning. BFT is the preferred conditioning regimen used in Precision-T, the ongoing Phase 3 pivotal study of Orca-T. Additionally, across all 151 patients, there was an increase in graft-versus-host disease-free, relapse-free survival (GRFS) rates and overall survival rates at one year with Orca-T compared to an independent cohort.“Today, providers must balance treatment decisions with the goal of fighting cancer while minimizing toxicities. With a standard allogeneic transplant, highly myeloablative conditioning regimens can lead to reduced rates of patient relapse, but can also increase rates of non-relapse mortality,” said Everett Meyer, M.D., Ph.D., primary investigator

Orca Bio Presents Data Demonstrating Its Lead Investigational High-Precision Cell Therapy Orca-T Significantly Improved Relapse-Free Survival At 64Th Ash Annual Meeting

Orca Bio to present at the 43rd Annual J.P. Morgan Healthcare Conference.

Orca Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Develops and commercializes cell therapies

Orca Bio

Develops and commercializes cell therapies

Orca Bio

Develops and commercializes cell therapies

About

Simplify's Take

What believers are saying

What critics are saying

What makes Orca Bio unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Orca Bio is Hiring for 0 Jobs on Simplify!